MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waeber, C.
Right arrow Articles by Moskowitz, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waeber, C.
Right arrow Articles by Moskowitz, M. A.

0026-895X/97/040623-09$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:623-631 (1997).

5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Receptors Stimulate [35S]Guanosine-5'-O-(3-thio)triphosphate Binding to Rodent Brain Sections as Visualized by In Vitro Autoradiography

Christian Waeber and Michael A. Moskowitz

Stroke and Neurovascular Regulation, Neurosurgery Service, Department of Surgery, Neurology Service, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129

[35S]Guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgamma S) binding to G proteins was measured by in vitro autoradiography in guinea pig and rat brain sections after activation by 5-hydroxytryptamine (5-HT) receptor agonists. 5-Carboxamidotryptamine stimulated binding strongly in hippocampus and lateral septum and weakly in substantia nigra. This effect was blocked in the substantia nigra by the 5-HT1B/1D receptor antagonist GR-127,935 and in the former two regions by the 5-HT1A antagonist NAN-190. 5-HT1B/1D receptor agonists stimulated binding in substantia nigra and in areas containing 5-HT1A receptors. In guinea pig substantia nigra, 5-(nonyloxy)-tryptamine maximally stimulated [35S]GTPgamma S binding by 54%, with an EC50 value of 62 nM; at 100 µM, this agonist increased binding by ~200% in hippocampus (with a 2-fold weaker EC50 value). The distribution of [3H]8-OH-DPAT binding sites was identical to that of the [35S]GTPgamma S labeling stimulated by the 5-HT1A agonist (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT)]. (R)-8-OH-DPAT, (S)-8-OH-DPAT, and buspirone stimulated [35S]GTPgamma S binding in hippocampus by 340%, 140%, and 78%, with EC50 values of 71, 51, and 132 nM. Enhanced [35S]GTPgamma S binding was not detected in the presence of 5-HT1F, 5-HT2, 5-HT4, and 5-HT7 receptor agonists. Because activation of µ-opioid, muscarinic M2, histamine H3, and cannabinoid receptors was also visualized successfully, these data suggest that only receptors coupled to pertussis toxin-sensitive G proteins can be seen by [35S]GTPgamma S binding autoradiography. This study also shows that different 5-HT receptors coupled to these proteins can show a wide range of [35S]GTPgamma S binding stimulation. Although the functional significance of these variations is unclear, this technique offers advantages over receptor autoradiography because it does not require high affinity radioligands and provides a measure of agonist efficacies in various brain regions.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. E. Culm and R. P. Hammer Jr.
Recovery of Sensorimotor Gating without G Protein Adaptation after Repeated D2-Like Dopamine Receptor Agonist Treatment in Rats
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 487 - 494.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Q. Li, C. Wichems, A. Heils, K.-P. Lesch, and D. L. Murphy
Reduction in the Density and Expression, But Not G-Protein Coupling, of Serotonin Receptors (5-HT1A) in 5-HT Transporter Knock-Out Mice: Gender and Brain Region Differences
J. Neurosci., November 1, 2000; 20(21): 7888 - 7895.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
V. Fabre, B. Boutrel, N. Hanoun, L. Lanfumey, C. M. Fattaccini, B. Demeneix, J. Adrien, M. Hamon, and M.-P. Martres
Homeostatic Regulation of Serotonergic Function by the Serotonin Transporter As Revealed by Nonviral Gene Transfer
J. Neurosci., July 1, 2000; 20(13): 5065 - 5075.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Meller, H. Li, K. D. Carr, and J. M. Hiller
5-Hydroxytryptamine1A Receptor-Stimulated [35S]GTPgamma S Binding in Rat Brain: Absence of Regional Differences in Coupling Efficiency
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 684 - 691.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
P. Bonaventure, L. Umans, M. H. M. Bakker, P. Cras, X. Langlois, W. H. M. L. Luyten, A. A. H. P. Megens, L. Serneels, F. Van Leuven, and J. E. Leysen
Humanization of Mouse 5-Hydroxytryptamine1B Receptor Gene by Homologous Recombination: In Vitro and In Vivo Characterization
Mol. Pharmacol., July 1, 1999; 56(1): 54 - 67.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
H. K. Happe, D. B. Bylund, and L. C. Murrin
Alpha-2 Adrenergic Receptor Functional Coupling to G Proteins in Rat Brain During Postnatal Development
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1134 - 1142.
[Abstract] [Full Text]


Home page
J Biomol ScreenHome page
D. S. Gembitsky, S. Lovas, and R. F. Murphy
Development of a High Throughput Functional Assay for Structure-Activity Studies of Neurokinin A Analogs
J Biomol Screen, April 1, 1998; 3(3): 183 - 188.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics